Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04399837
Registration number
NCT04399837
Ethics application status
Date submitted
20/05/2020
Date registered
22/05/2020
Date last updated
14/12/2023
Titles & IDs
Public title
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
Query!
Scientific title
Effisayil™ 2: Multi-center, Randomized, Parallel Group, Double Blind, Placebo Controlled, Phase IIb Dose-finding Study to Evaluate Efficacy and Safety of BI 655130 (Spesolimab) Compared to Placebo in Preventing Generalized Pustular Psoriasis (GPP) Flares in Patients With History of GPP.
Query!
Secondary ID [1]
0
0
2018-003081-14
Query!
Secondary ID [2]
0
0
1368-0027
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Generalized Pustular Psoriasis
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Spesolimab
Treatment: Drugs - Placebo
Experimental: Spesolimab SC low dose -
Experimental: Spesolimab SC medium dose -
Experimental: Spesolimab SC high dose -
Placebo comparator: Placebo -
Treatment: Drugs: Spesolimab
Solution for injection
Treatment: Drugs: Placebo
Solution for injection
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Time to First Generalized Pustular Psoriasis (GPP) Flare
Query!
Assessment method [1]
0
0
A GPP flare was defined as increase in Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score by = 2 from baseline and the pustular component of GPPGA = 2) up to week 48. Use of rescue medication, or investigator-prescribed Standard of Care (SoC) for GPP worsening, was considered to represent a GPP flare onset.
GPPGA relied on clinical assessment of the Generalized Pustular Psoriasis (GPP) patient's skin presentation. The GPPGA total score was calculated by taking the mean of the erythema subscore, pustules subscore and scaling/crusting subscore. The severity of each subscore was assessed using a 5 point scale score ranging from 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). The final GPPGA score is assigned as follows:
* 0 , if scores for all three subscores are 0,
* 1, if 0 \< mean \< 1.5,
* 2, if 1.5 = mean \< 2.5,
* 3, if 2.5 = mean \< 3.5,
* 4, if mean = 3.5.
Query!
Timepoint [1]
0
0
GPPGA was regularly assessed at baseline (Week 1) and up to Week 48 (at Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48). Patients could come to site for flare confirmation anytime as unscheduled visit. Visit window was ±7 days.
Query!
Secondary outcome [1]
0
0
Key Secondary Endpoint: The Occurrence of at Least One Generalized Pustular Psoriasis (GPP) Flare up to Week 48
Query!
Assessment method [1]
0
0
Proportion of patients with at least one GPP flare up to Week 48 is reported. Proportions were rounded up to three decimal places.
A GPP flare was defined as increase in Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score by = 2 from baseline and the pustular component of GPPGA = 2. Any use of rescue medication, or investigator-prescribed SoC for GPP worsening, prior to week 48 was considered to represent the onset of a GPP flare.
Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) relied on the clinical assessment of GPP patient's skin presentation. The total score is calculated by taking the mean of the three subscores: 1) erythema; 2) pustules and 3) scaling/crusting which were assessed using a scale score 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). The final GPPGA score:
0 , if scores for all three subscores are 0,
1. if 0 \< mean \< 1.5;
2. if 1.5 = mean \< 2.5;
3. if 2.5 = mean \< 3.5;
4. if mean = 3.5.
Query!
Timepoint [1]
0
0
GPPGA was regularly assessed at baseline (Week 1) and up to Week 48 (at Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48). Patients could come to site for flare confirmation anytime as unscheduled visit. Visit window was ±7 days.
Query!
Secondary outcome [2]
0
0
Time to First Worsening of Psoriasis Symptom Scale (PSS) up to Week 48
Query!
Assessment method [2]
0
0
Worsening of Psoriasis Symptom Scale (PSS) was defined as a 4-point increase in total score from baseline. Intake of rescue medication, or investigator-prescribed SoC for GPP worsening, was considered as onset of a worsening.
The PSS is a 4-item patient-reported outcome (PRO) instrument that was developed to assess the severity of 4 psoriasis symptoms in patients with moderate to severe psoriasis.
The symptoms included are: pain, redness, itching, and burning. Current symptom severity is assessed using a 5-point scale ranging from 0 (none) to 4 (very severe). The symptom scores are added to an unweighted total score (range: 0 (no symptoms) to 16 (severe symptoms)).
Query!
Timepoint [2]
0
0
PSS assessments were performed at: Baseline (Week 1) and up to Week 48 (at Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48). Visit window was ±7 days.
Query!
Secondary outcome [3]
0
0
Time to First Worsening of Dermatology Quality of Life Index (DLQI) up to Week 48
Query!
Assessment method [3]
0
0
Worsening of DLQI up to week 48 was defined as a 4-point increase in total score from baseline. Intake of rescue medication, or investigator-prescribed SoC for GPP worsening, was considered as onset of a worsening.
The DLQI is a patient-administered, ten-question, quality of life questionnaire that covers six domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment. Response categories include "not relevant" (score of 0), "not at all" (score of 0), "a little" (score of 1), "a lot" (score of 2) and "very much" (score of 3). Question 7 is a "yes"/ "no" question where "yes" is scored as 3. DLQI total score is calculated by summing the scores of each question resulting in a range of 0 (no effect on patient's life) to 30 (extremely large effect on patient's life).
Query!
Timepoint [3]
0
0
DLQI assessments were performed at: Baseline (Week 1) and up to Week 48 (at Week 4, 8, 12, 24, 36 and 48). Visit window was ±7 days. Time window for Week 48 was from Week 46 to Week 50.
Query!
Secondary outcome [4]
0
0
Sustained Remission
Query!
Assessment method [4]
0
0
Proportion of patients with sustained remission at all visits up to Week 48. Proportions were rounded up to three decimal places.
Remission was defined as a patient with a GPPGA score of 0 or 1 (clear or almost clear) at all visits up to week 48, without intake of rescue medication, or investigator-prescribed SoC for GPP worsening.
GPPGA relied on clinical assessment of the Generalized Pustular Psoriasis (GPP) patient's skin presentation. The GPPGA total score was calculated by taking the mean of the erythema subscore, pustules subscore and scaling/crusting subscore. The severity of each subscore was assessed using a 5 point scale score ranging from 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). The final GPPGA score is assigned as follows:
* 0 , if scores for all three subscores are 0,
* 1, if 0 \< mean \< 1.5,
* 2, if 1.5 = mean \< 2.5,
* 3, if 2.5 = mean \< 3.5,
* 4, if mean = 3.5.
Query!
Timepoint [4]
0
0
GPPGA was regularly assessed at baseline (Week 1) and up to Week 48 (at Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48). Patients could come to site for flare confirmation anytime as unscheduled visit. Visit window was ±7 days.
Query!
Secondary outcome [5]
0
0
The Occurrence of Treatment Emergent Adverse Events (TEAEs)
Query!
Assessment method [5]
0
0
Percentage of patients with treatment emergent adverse events (TEAEs) is reported. Percentages were rounded up to one decimal places.
Time Frame: Placebo, Spesolimab (Speso) SC low, medium, high: From randomized study treatment start until the first use of rescue medication with IV spesolimab or until last dose + 16 weeks, up to 62 weeks.
Speso IV SD and Speso IV DD: From first use of rescue medication with IV spesolimab until OL maintenance spesolimab SC or until last dose of spesolimab IV + 16 weeks, up to 17 weeks.
Speso OL SC: From the first dose of OL spesolimab SC treatment until last dose + 16 weeks, up to 62 weeks.
Query!
Timepoint [5]
0
0
Up to 62 weeks (for detailed timeframe see description).
Query!
Eligibility
Key inclusion criteria
* Patients with a known and documented history of GPP per ERASPEN criteria (see Section 3.3.1) regardless of IL36RN mutation status, with at least 2 presentations of moderate to severe GPP flares with fresh pustulation (new appearance or worsening) in the past.
* Patients with a GPPGA score of 0 or 1 at screening and randomization.
* Patients who are not on concomitant GPP treatment at time of randomization (V2) must have had at least two presentations of moderate to severe GPP flare in the past year, at least one of which had evidence of either fever and/or elevated CRP and/or elevated WBC, and/or asthenia and/or myalgia.
* Patients who are not on concomitant GPP treatment at time of randomization (V2) but who were on concomitant GPP treatment until shortly before randomization (V2) (= 12 weeks before randomization), these patients must have a history of flaring while on concomitant treatment for GPP or in case of dose reduction or discontinuation of their concomitant medication.
* Patients who are on concomitant treatment regimen with retinoids and/or methotrexate and/or cyclosporine must stop at the day of randomization (V2). These patients must have a history of flaring while on concomitant treatment for GPP or in case of dose reduction or discontinuation of these concomitant medications.
* Male or female patients, aged 12 to 75 years at screening. For all patients, a minimum weight of 40 kg is required.
* Signed and dated written informed consent and assent in accordance with ICH-GCP and local legislation prior to admission in the trial.
* Women of childbearing potential (WOCBP)1 must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the CTP as well as in the patient, parent(s) (or patient's legal guardian) information.
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Patients with SAPHO (Synovitis-acne-pustulosis-hyperostosis-osteitis) syndrome.
2. Patients with primary erythrodermic psoriasis vulgaris.
3. Severe, progressive, or uncontrolled hepatic disease, defined as >3-fold Upper Limit of Normal (ULN) elevation in Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) or alkaline phosphatase, or >2-fold ULN elevation in total bilirubin.
4. Treatment with:
1. Any restricted medication as specified in the CTP, or any drug considered likely to interfere with the safe conduct of the study, as assessed by the investigator.
2. Any prior exposure to BI 655130 or another IL36R inhibitor biologic.
5. Increased risk of infectious complications (e.g. recent pyogenic infection, any congenital or acquired immunodeficiency (e.g. HIV), past organ or stem cell transplantation), as assessed by the investigator.
6. Relevant chronic or acute infections including active tuberculosis, human immunodeficiency virus (HIV) infection or viral hepatitis at the time of randomization. A patient can be re-screened if the patient was treated and is cured from the acute infection.
7. Active or Latent Tuberculosis (TB):
* Patients with active tuberculosis should be excluded
* Patients with a positive QuantiFERON® (or if applicable, T-Spot®) TB test during screening are excluded, unless the patient had previous diagnosis of active or latent TB and has completed appropriate treatment per the discretion of the local investigator within the last 3 years and at the latest at the time of screening (i.e. 2 to 4 weeks before study drug administration); patients may be re-screened once to meet this criterion)
* Patients with suspected false positive or indeterminate QuantiFERON® (or if applicable, T-Spot®) TB result may be re-tested once
* If QuantiFERON® (or if applicable, T-Spot®) TB testing is not available or provides indeterminate results after repeat testing, a tuberculin skin test (TST) can be performed: A TST reaction of =10mm (=5mm if receiving =15mg/d prednisone or its equivalent) is considered positive.
8. History of allergy/hypersensitivity to the systemically administered trial medication agent or its excipients.
Further exclusion criteria apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
4/06/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
23/11/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
123
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Michigan
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Missouri
Query!
Country [3]
0
0
Argentina
Query!
State/province [3]
0
0
Caba
Query!
Country [4]
0
0
Belgium
Query!
State/province [4]
0
0
Bruxelles
Query!
Country [5]
0
0
Chile
Query!
State/province [5]
0
0
Vitacura
Query!
Country [6]
0
0
China
Query!
State/province [6]
0
0
Guangzhou
Query!
Country [7]
0
0
China
Query!
State/province [7]
0
0
Hangzhou
Query!
Country [8]
0
0
China
Query!
State/province [8]
0
0
Shanghai
Query!
Country [9]
0
0
China
Query!
State/province [9]
0
0
Shenyang
Query!
Country [10]
0
0
China
Query!
State/province [10]
0
0
Tianjin
Query!
Country [11]
0
0
China
Query!
State/province [11]
0
0
Xi'an
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Nice
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Paris
Query!
Country [14]
0
0
Germany
Query!
State/province [14]
0
0
Bad Bentheim
Query!
Country [15]
0
0
Germany
Query!
State/province [15]
0
0
Bonn
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Frankfurt am Main
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
München
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Münster
Query!
Country [19]
0
0
Germany
Query!
State/province [19]
0
0
Oldenburg
Query!
Country [20]
0
0
Germany
Query!
State/province [20]
0
0
Würzburg
Query!
Country [21]
0
0
Greece
Query!
State/province [21]
0
0
Thessaloniki
Query!
Country [22]
0
0
Italy
Query!
State/province [22]
0
0
Rozzano (MI)
Query!
Country [23]
0
0
Japan
Query!
State/province [23]
0
0
Aichi, Nagoya
Query!
Country [24]
0
0
Japan
Query!
State/province [24]
0
0
Fukuoka, Kitakyushu
Query!
Country [25]
0
0
Japan
Query!
State/province [25]
0
0
Ibaraki, Inashiki-gun
Query!
Country [26]
0
0
Japan
Query!
State/province [26]
0
0
Saitama, Iruma-gun
Query!
Country [27]
0
0
Japan
Query!
State/province [27]
0
0
Tokyo, Hachioji
Query!
Country [28]
0
0
Japan
Query!
State/province [28]
0
0
Tokyo, Shinjuku-ku
Query!
Country [29]
0
0
Korea, Republic of
Query!
State/province [29]
0
0
Busan
Query!
Country [30]
0
0
Korea, Republic of
Query!
State/province [30]
0
0
Seoul
Query!
Country [31]
0
0
Malaysia
Query!
State/province [31]
0
0
Ipoh
Query!
Country [32]
0
0
Malaysia
Query!
State/province [32]
0
0
Johor Bahru
Query!
Country [33]
0
0
Malaysia
Query!
State/province [33]
0
0
Kota Kinabalu
Query!
Country [34]
0
0
Malaysia
Query!
State/province [34]
0
0
Kuala Lumpur
Query!
Country [35]
0
0
Malaysia
Query!
State/province [35]
0
0
Kuching, Sarawak
Query!
Country [36]
0
0
Malaysia
Query!
State/province [36]
0
0
Muar
Query!
Country [37]
0
0
Malaysia
Query!
State/province [37]
0
0
Pulau Pinang
Query!
Country [38]
0
0
Mexico
Query!
State/province [38]
0
0
Guadalajara
Query!
Country [39]
0
0
Mexico
Query!
State/province [39]
0
0
Monterrey
Query!
Country [40]
0
0
Netherlands
Query!
State/province [40]
0
0
Rotterdam
Query!
Country [41]
0
0
Philippines
Query!
State/province [41]
0
0
Davao City
Query!
Country [42]
0
0
Philippines
Query!
State/province [42]
0
0
Iloilo City, Iloilo
Query!
Country [43]
0
0
Philippines
Query!
State/province [43]
0
0
Makati City
Query!
Country [44]
0
0
Russian Federation
Query!
State/province [44]
0
0
Chelyabinsk
Query!
Country [45]
0
0
Russian Federation
Query!
State/province [45]
0
0
Kazan
Query!
Country [46]
0
0
Russian Federation
Query!
State/province [46]
0
0
Kirov
Query!
Country [47]
0
0
Russian Federation
Query!
State/province [47]
0
0
Saint-Petersburg
Query!
Country [48]
0
0
Russian Federation
Query!
State/province [48]
0
0
Saratov
Query!
Country [49]
0
0
Russian Federation
Query!
State/province [49]
0
0
St. Petersburg
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a study in adolescents and adults with Generalized Pustular Psoriasis (GPP). People between 12 and 75 years old can take part in the study. The study is open to people who had GPP flare-ups in the past but whose skin is clear or almost clear when they join the study. The purpose of the study is to test 3 different doses of a medicine called spesolimab and to see whether it helps to prevent GPP flare-ups. Participants are put into 4 groups by chance. Three groups get different doses of spesolimab. The fourth group gets a placebo. Placebo looks like spesolimab but does not contain any medicine. Spesolimab and placebo are given as an injection under the skin. Participants are in the study for about 1 year and 4 months. During this time, they visit the study site about 15 times. For the first 11 months, participants get spesolimab or placebo injections every month. At the study visits, the doctors check participants' skin for signs of a new GPP flare-up. The doctors also check the general health of the participants. If a participant has a GPP flare-up during the study, more visits may be necessary. In case of a flare-up, participants get a dose of spesolimab as an infusion into a vein.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04399837
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT04399837
Download to PDF